UNSPSC 51282009: Chloramphenicol palmitate

This classification denotes an antibiotic with the molecular formula C27H42Cl2N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 43VU4207NW, chemically known as palmitic acid, alpha-ester with d-threo-(-)-2,2-dichloro-n-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)acetamide but more generally known as chloramphenicol palmitate, which bears US NIH Compound Identifier 10736. European Medicines Agency schedules Chloramphenicol palmitate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01206MIG.

UNSPSC 51282009 Chloramphenicol palmitate is a Commodity code covering a specific antibiotic pharmaceutical product that state and local governments procure through cooperative purchasing agreements for distribution to government healthcare facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is actively soliciting manufacturers and authorized distributors of generic multi-source pharmaceuticals and over-the-counter products under a broader framework that includes this drug code. State and local buyers acquire chloramphenicol palmitate and similar generic pharmaceuticals through established wholesale distribution channels—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC—and evaluate vendors on price competitiveness (weighted at 75 percent of evaluation), compliance with FDA and current Good Manufacturing Practices (cGMP) standards, Drug Supply Chain Security Act (DSCSA) certification, electronic data interchange capability, and fixed pricing structures. Vendors must maintain contractual relationships with at least two of the three authorized wholesalers with chargeback systems in place and carry comprehensive insurance including $5,000,000 commercial general liability per occurrence.

MMCAP's January 2026 RFP for generic multi-source pharmaceuticals spans Minnesota and Oregon, with proposals due March 26, 2026. The solicitation requires product availability by May 15, 2026, and effective contract dates of July 1, 2026, with a two-year initial term and optional extensions through June 30, 2028. Vendors submit detailed product information including National Drug Codes, SKUs, UPCs, strength, dosage form, and packaging configurations in Excel format via the ePro procurement system, with pricing submitted using flat-price, net-price (NF30, NF60, NF90), or WAC-minus formats. All products must meet FDA requirements, possess expiration dates of at least one year from manufacture, and maintain a minimum six-month shelf life. Vendors are subject to a 3 percent administrative fee on all contract purchases and performance penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials. No specific award values are disclosed in the solicitation.